Disorders of Sex Development: Clinical Trials

38 trials for Disorders of Sex Development, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed, 6 recruiting, 5 active not recruiting, 2 unknown. 38 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 338Completed 23, Recruiting 6, Active not recruiting 5, Unknown 2, Not yet recruiting 1, Withdrawn 1
Phase 23Completed 1, Recruiting 1, Unknown 1

Follow Disorders of Sex Development: new trials by email Literature Review of Disorders of Sex Development trials Research Report on Disorders of Sex Development

Trials (filtered) newest first · largest first

All 38 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
Semaglutide (Wegovy) weekly injection, Placebo weekly Injection - Craniopharyngioma, Child
Phase 3Not yet recruitingUniversity Hospital, Angers502026-11-012026-09-29
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Inpegsomatropin-Injection, Givopegsomatropin Solution Injection - Turner Syndrome
Phase 3RecruitingXiamen Amoytop Biotech Co., Ltd.842026-07-052026-07-22
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Phase 2 / Phase 3RecruitingCrinetics Pharmaceuticals Inc.1532026-01-222026-11-10
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector - Turner Syndrome, Short Stature Homeobox Gene Mutation
Phase 3RecruitingAscendis Pharma A/S1862025-12-122026-11-05
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Phase 3RecruitingCrinetics Pharmaceuticals Inc.1502025-12-112026-11-10
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Setmelanotide, Placebo - Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form
Phase 3RecruitingRhythm Pharmaceuticals, Inc.392025-09-232026-02-12
Open-Label Extension Study of Setmelanotide
Setmelanotide - Obesity Associated With Defects in Leptin-melanocortin Pathway
Phase 3CompletedRhythm Pharmaceuticals, Inc.282024-10-212026-07-15
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Setmelanotide, Placebo - Hypothalamic Obesity
Phase 3Active not recruitingRhythm Pharmaceuticals, Inc.1432023-04-262026-08-10
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
Anastrozole, Semaglutide, human chorionic gonadotropin - Klinefelter Syndrome
Phase 3RecruitingGeorgios Papadakis1502023-03-212026-05-11
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
Somapacitan - SGA, Turner Syndrome
Phase 3Active not recruitingNovo Nordisk A/S472023-02-012026-08-13
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
Somapacitan, Norditropin® - SGA, Turner Syndrome, Noonan Syndrome, ISS
Phase 3Active not recruitingNovo Nordisk A/S4122022-08-102026-06-12
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Chronocort, Cortef, Placebo - Congenital Adrenal Hyperplasia
Phase 3CompletedNeurocrine UK Limited552022-05-242026-10-02
Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia
Chronocort - Congenital Adrenal Hyperplasia
Phase 3CompletedImmedica Pharma AB762022-04-012026-06-18
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Crinecerfont, Placebo - Congenital Adrenal Hyperplasia
Phase 3Active not recruitingNeurocrine Biosciences1032021-06-252025-02-05
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study
Testosterone gel, Placebo - Disorder of Sex Development, 46,XY
Phase 3UnknownErasmus Medical Center12021-06-012021-04-05
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Crinecerfont, Placebo - Congenital Adrenal Hyperplasia
Phase 3Active not recruitingNeurocrine Biosciences1822020-12-162026-05-11
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy
Chronocort®, Standard Care - Congenital Adrenal Hyperplasia
Phase 3WithdrawnNeurocrine UK Limited2018-10-042026-09-14
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
Exenatide, Placebo - Craniopharyngiomas, Hypothalamic Obesity
Phase 3CompletedUniversity Hospital, Bordeaux422017-01-112026-05-22
A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
Hydrocortisone - Congenital Adrenal Hyperplasia
Phase 3CompletedNeurocrine UK Limited912016-08-182026-10-02
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Exenatide, placebo - Hypothalamic Obesity
Phase 3CompletedSeattle Children's Hospital422016-03-012022-05-05

Showing 20 of 38. Sign in to see all of them.

Narrower conditions

Turner Syndrome (14)  ·  Adrenal Hyperplasia, Congenital (11)  ·  Sexual Infantilism (6)  ·  Dwarfism (4)  ·  Genetic Diseases, Inborn (3)  ·  Infertility (3)  ·  Noonan Syndrome (3)  ·  Craniopharyngioma (2)  ·  Failure to Thrive (2)  ·  Hyperandrogenism (2)  ·  Hypogonadism (2)  ·  Klinefelter Syndrome (2)  ·  Obesity (2)  ·  Polycystic Ovary Syndrome (2)

Broader conditions

Congenital Abnormalities (38)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (38)  ·  Female Urogenital Diseases (38)  ·  Female Urogenital Diseases and Pregnancy Complications (38)  ·  Gonadal Disorders (38)  ·  Male Urogenital Diseases (38)  ·  Urogenital Abnormalities (38)  ·  Urogenital Diseases (38)  ·  Endocrine System Diseases (37)  ·  Genetic Diseases, Inborn (25)  ·  Gonadal Dysgenesis (20)  ·  Chromosome Disorders (15)  ·  Sex Chromosome Disorders (15)  ·  Sex Chromosome Disorders of Sex Development (15)

Interventions

Human Growth Hormone (7)  ·  Hydrocortisone (5)  ·  setmelanotide (3)  ·  Dexamethasone (2)  ·  Estradiol (2)  ·  Exenatide (2)  ·  Growth Hormone (2)  ·  Prednisolone (2)  ·  Prednisone (2)  ·  asenapine (2)  ·  crinecerfont (2)  ·  semaglutide (2)  ·  somapacitan (2)  ·  Anastrozole (1)  ·  Androgens (1)

Sponsors

Novo Nordisk A/S (5)  ·  Neurocrine UK Limited (4)  ·  Rhythm Pharmaceuticals, Inc. (3)  ·  Crinetics Pharmaceuticals Inc. (2)  ·  Eli Lilly and Company (2)  ·  Neurocrine Biosciences (2)  ·  Organon and Co (2)  ·  59th Medical Wing (1)  ·  Ascendis Pharma A/S (1)  ·  Dong-A ST Co., Ltd. (1)  ·  Erasmus Medical Center (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Ferring Pharmaceuticals (1)  ·  Georgios Papadakis (1)  ·  Immedica Pharma AB (1)

Countries

United States (22)  ·  France (13)  ·  United Kingdom (9)  ·  Germany (8)  ·  Italy (8)  ·  Netherlands (8)  ·  Spain (7)  ·  Canada (6)  ·  Poland (6)  ·  Belgium (5)  ·  Japan (5)  ·  Greece (4)  ·  South Korea (4)  ·  Austria (3)  ·  Brazil (3)

Top investigators

David Meeker, MD (3)  ·  Andrea Isidori, MD, PhD (1)  ·  Andrea Lenzi, MD (1)  ·  Blandine Gatta-Cherifi, Pr (1)  ·  Byung Kyu Suh, M.D., Ph.D. (1)  ·  Chang Jong Kim, M.D., Ph.D. (1)  ·  Cheol Woo Ko, M.D., Ph.D. (1)  ·  Choong Ho Shin, M.D., Ph.D. (1)  ·  Christian Roth, MD (1)

Results publications

PMID 26091193, PMID 33527139, PMID 15784709, PMID 16757526, PMID 20733274, PMID 21619701, PMID 31532522, PMID 34893062, PMID 38450721, PMID 38828945, PMID 38828955, PMID 39672600, PMID 41712606, PMID 41774755, PMID 42418774, PMID 42528856, PMID 42821228

NIH funding

2009 (2), 2023 (2), 2004 (1), 2019 (1)